This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Arena Fans Spinning (And Altering) Belviq Prescription Data

Stocks in this article: ARNA VVUS

ARNA Chart ARNA data by YCharts

SAN DIEGO ( TheStreet) -- Arena Pharmaceuticals' (ARNA) most ardent shareholders -- a group of retail investors known affectionately known as the Areniacs -- are unhappy with the early prescription numbers for the company's weight-loss pill Belviq, so they're making up their own numbers.

Doctors wrote 1,829 prescriptions for Belviq for the week ended June 21, a 68 percent increase over the 1,087 scripts written the week before, according to IMS Health.

Arena and its marketing partner Eisai began selling Belviq on June 11. It's hard to say much about two weeks of prescription data but that matters little to Arena's retail investors because they've brainwashed themselves into believing the marginally effective weight loss pill would be an instant blockbuster.

When Belviq weekly scripts didn't double, triple or even quadruple this week, as they expected (unrealistically), the Areniacs blamed IMS, short sellers and anyone or anything other than the drug or themselves.

"Because IMS data is only 73% accurate, I adjusted it to estimate actual number of scripts and based my analysis on the adjusted number," writes "Reasonable Risk," in a Seeking Alpha column Monday titled Improper Analysis of Belviq's IMS Prescription Data Causes A 9% Sell-Off Of Arena On Good News.

"Reasonable Risk" doesn't explain how he reached the conclusion that IMS reporting of weekly Belviq prescription is only 73 percent accurate. It's true that IMS weekly prescription data are rarely 100 percent accurate so require adjustments, but two weeks of data is not enough to calculate an error rate. The anonymous author of the Seeking Alpha article starts with the conclusion that Belviq's early launch must be going great, so if actually reported IMS data aren't supportive, "adjust" the data to make them look better.

Unfortunately, even his adjusted analysis of Belviq scripts isn't looking too hot:

"A linear growth rate based on the second week's 501 scripts per workday suggests pharmacies will fill about 9,000 scripts the first month. Although that is about 30% below my predicted initial estimate, two data points are inadequate for making predictions," he writes. Emphasis mine.

Are two weeks of Belviq prescriptions numbers adequate or not? "Reasonable Risk" can't seem to make up his mind.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs